Decoding Symptoms: When Fatigue Speaks Volumes
Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.
EP: 1.Recognizing PNH and Initial Challenges
EP: 2.Empowering Patients in Treatment Planning
EP: 3.Navigating Treatment Options: Understanding Risks and Benefits
EP: 4.Decoding Symptoms: When Fatigue Speaks Volumes
EP: 5.Starting Treatment: Insights and Initial Experiences
EP: 6.Living With PNH: Long-Term Management and Caregiver Support
EP: 7.Patient Voices: Shaping the Future of PNH Care
EP: 8.Closing Reflection: A Journey of Understanding and Resilience
Video content above is prompted by the following:
- How do you help patients weigh the risks and benefits of different treatment options?
- What tools or techniques do you use to ensure patients and caregivers fully understand their choices?
This program was made possible with support from Novartis Pharmaceuticals.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
